


***In the name of God***





# *vectors in gene therapy*




*Presented by : Sahar khojasteh pour*

*Under supervision of : Dr. Ahmadvour*

*30 may 2016*

Medical of Biotechnology group  
Qazvin University medical Sciences



# Contents

## ➤ *Introduction*

- ✓ Genes
- ✓ What is Gene Therapy?
- ✓ History
- ✓ How It Works
- ✓ Types of genetherapy
- ✓ challenges in gene therapy
- ✓ Gene therapy targets

## ➤ *Discussion*

- ✓ Vectors in genetherapy
- ✓ Strategies for Transgene Delivery
- ✓ Types of vector

## ➤ *Conclusion*


- ✓ Advantage and disadvantages of vectors

## ➤ *Refrences*





# Genes




# *What is Gene Therapy?*

- ❑ A technique for correcting defective.(1)
- ❑ A normal gene inserted to compensate for a nonfunctional gene.(1)
- ❑ There are approaches:(2)
  - An abnormal gene traded for a normal gene
  - An abnormal gene repaired through selective reverse mutation
  - Change the regulation of gene pairs

# *What is Gene Therapy?*

- ✓ treat, cure, or ultimately prevent disease by changing the expression of a person's genes.(3)
- ✓ current gene therapy is primarily experimental, with most human clinical trials only in the research stages.(4)
- ✓ Transfer of genetic material to cure a disease or at least to improve the clinical status.(4)





# *History*

- ✓ The origins is the first live attenuated vaccines in the **1950s**.<sup>(5)</sup>
- ✓ The concept of gene therapy arose during the **1960s** and **1970s**.<sup>(5)</sup>
- ✓ In **1972**, Theodore Friedmann and Richard Roblin published a paper in Science called "Gene therapy for human genetic disease?".<sup>(5)</sup>



# *History*

- ✓ The first attempt at modifying human DNA was performed in **1980** by Martin Cline. (6)
- ✓ In **1985**, Anderson and colleague demonstrated how cells from people with ADA deficiency could be modified in tissue culture. (6)
- ✓ The first successful and approved nuclear gene transfer in humans was performed in may **1989** by Dr. Steven Rosenberg. (6)

# History

✓ **1990** - The first approved gene therapy clinical trial took place when Ashanthi DeSilva, with ADA-deficient Severe Combined Immunodeficiency. (7)

**The First gene therapy case was performed on September 14<sup>th</sup>, 1990.**



- Ashanti De Silva was treated for SCID (Severe combined immunodeficiency).
- Doctors removed her white blood cells, inserted the missing gene into the WBC, and then put them back into her blood stream.
- This strengthened her immune system
- This only worked for a few months.



# *How It Works*

- ✓ A **vector** delivers the therapeutic gene.(8)
- ✓ The vector's genetic material is **inserted** into the target cell.(8)
- ✓ **Functional proteins** are created from the therapeutic gene.(8)

# *Three types of gene therapy:*

## ➤ *Monogenic gene therapy*

- Provides genes to encode for the production of a specific protein
- Cystic fibrosis, Muscular dystrophy.(9)

## ➤ *Suicide gene therapy*

- Provide 'suicide' genes to target cancer cells for destruction(9)

## ➤ *Antisense gene therapy*

- Provides a single stranded gene in an 'antisense' orientation to block the production of harmful proteins.
- AIDS/HIV(9)



# *challenges in gene therapy*<sup>(4)</sup>

*Immune Response*

*Short Lived*

*challenges*

*Viral Vectors*

*Multi gene Disorders*

# *Gene therapy targets*

➤ *Germ line gene therapy*<sup>(9)</sup>

➤ *Somatic cell gene therapy*<sup>(9)</sup>


- Gene augmentation
- Gene replacement
- Specific inhibition of gene expression
- Targeted cell death



# Gene therapy targets

## ➤ Gene augmentation


- Add a useful gene into a selected cell type to **compensate** for the missing or flawed version.(10)
- Useful in treating loss of function mutations.(10)



# Gene therapy targets

## ➤ Gene replacement

- **Replaces** the mutant copy with a correctly functioning copy in situ.(10)
- Useful for gain of function mutations such as oncogenes.(10)




# Gene therapy targets

## ➤ *Specific inhibition of gene expression*

- Involves **silencing** of specific genes like activated oncogenes.
- Using molecules that degrade RNA transcripts. (10)

### ✓ Strategies include

- Antisense therapy
- siRNA (small interfering RNA)
- Ribozymes





# Gene therapy targets

## ➤ Targeted cell death

- Tissue specific toxicity as a result of gene therapy.(10)
- Useful in cancer therapy.(10)




Figure 21-4 part 2 of 3 Human Molecular Genetics, 3/e. (© Garland Science 2004)

# *Vectors in gene therapy*

- **Vectors** are carrier molecules which are employed to enhance gene transfer efficiency.(11)
- Ability to **transduce** dividing and non-dividing cells(11)
- Ability to **integrate** into a site-specific location in the host chromosome.(11)

# *Vectors in gene therapy*


➤ *In optimizing a particular vector, one must consider:*

- ✓ Host immune response(12)
- ✓ Must target specific tissues for long term gene expression(12)
- ✓ Regulation of the gene after insertion(12)




# *Strategies for Transgene Delivery*

## ❖ In vivo Gene Therapy(4)



## ❖ Ex vivo Gene Therapy(4)



# *Strategies for Transgene Delivery*

## ❖ *In vivo Gene Therapy*


- intravenous or intramuscular or non-invasive.
- Delivery of new genetic material **directly** to target cells within the body.(4)

## ❖ *Ex vivo Gene Therapy*


- target cells are **removed** from the body and then genetically modified.(4)
- The cells are then **returned to** the body after selection and amplification(4)
- This is **a safe method** but dependent on the type of cells being target.

# *Types of vector*

## ❖ Viral



## ❖ Non-Viral






# *Types of vector*

## ❖ *Viral vector*

- ✓ Virus particles provide a relatively efficient.(13)
- ✓ Viruses are highly evolved **natural vectors** for the transfer.(13)
  - ✓ Show some specificity
  - ✓ Immune reaction
  - ✓ Possible infection risk


# *Types of vector*



# *Types of vector*

## ❖ Non-viral Vectors

- non-toxic
- no immune response
- Lower tissue specificity
- Less efficient gen transfer than viruses






# *Types of vector*




# Types of vector

Vectors Used in Gene Therapy Clinical Trials



The Journal of Gene Medicine, © 2015 John Wiley and Sons Ltd

[www.wiley.co.uk/genmed/clinical](http://www.wiley.co.uk/genmed/clinical)



# Types of vector

## ❖ Non-viral Vectors

### Nonviral gene delivery

```
graph TD; A[Nonviral gene delivery] --> B[In vivo]; A --> C[In vitro]; B --> D[Naked DNA transfer by electroporation]; C --> E[Physical]; C --> F[Chemical]; E --> G[Electroporation]; E --> H[Gene gun]; E --> I[Microinjection]; E --> J[Ultrasound]; E --> K[Hydrodynamic delivery]; F --> L[Liposomes]; F --> M[Polymers]; F --> N[Dendriners];
```

#### *In vivo*

Naked DNA tranfer by electroporation

#### *In vitro*

#### Physical

*Electroporation*

*Gene gun*

*Microinjection*

*Ultrasound*

*Hydrodynamic delivery*

#### Chemical

*Liposomes*



*Polymers*

*Dendriners*



# *Types of vector*

## ❖ Non-viral Vectors



# *Types of vector*

## ❖ Non-viral vectors

### Chemical methods


Hybrid  
methods-

Dendrimers

Lipoplexes  
and  
polyplexes-

Oligonuc  
leotides

# *Types of vector*





# Advantage and disadvantages of vectors ➡

## Biologic viral vectors

Type of vectors	Integration To genome	Advantages	Disadvantages
<i>Retrovirus</i>	Yes	<ul style="list-style-type: none"><li>-Wide host range.</li><li>-high <b>efficiency</b>.</li><li>-transduction of <b><u>dividing cells</u></b>.</li><li>-<b>stable integration</b>.</li><li>- infects only once and does not replicate in vivo.</li></ul>	<ul style="list-style-type: none"><li>-Does not infect <b><u>non dividing</u></b></li><li>-insert size <b>5-7 kb</b>.</li></ul>
<i>Lentivirus (HIV)</i>	Yes	<ul style="list-style-type: none"><li>-Wide host range.</li><li>-stable transduction of <b>dividing and non dividing</b></li><li>-long term expression.</li><li>-<b>nonpathogenic</b>.</li><li>-lack of expression of <b>viral proteins</b>.</li></ul>	

Type of vectors	Integration To genome	Advantages	Disadvantages
<i>Adenovirus</i>	No	<ul style="list-style-type: none"> <li>- Transduction of <b>non dividing</b> cells with high efficiency.</li> <li>-wide host rang.</li> <li>-high viral <b>titer</b> and high expression levels.</li> <li>-newly developed gutless vectors have insert size as large as <b>30 kb</b>.</li> </ul>	<ul style="list-style-type: none"> <li>-Expression of viral proteins results in toxic reaction and inflammation.</li> <li>-<b>carcinogenic</b>.</li> <li>-low efficiency in dividing cells.</li> <li>-<b>short-term</b> expression.</li> <li>- insert size only <b>7-11 kb</b>.</li> </ul>
<i>Adeno-associated virus</i>	Yes	<ul style="list-style-type: none"> <li>-Transduction of <b>dividing and non dividing</b> cells.</li> <li>-<b>non immunogenic</b> and <b>nonpathogenic</b>.</li> <li>-<b>long-term expression</b> of transgene.</li> </ul>	<ul style="list-style-type: none"> <li>-<b>Limited</b> transduction efficiency.</li> <li>-low efficiency of integration to genome.</li> <li>-small insert size~<b>4-5 kb</b>.</li> </ul>

Type of vectors	Integration To genome	Advantages	Disadvantages
<i>Herpes simplex virus</i>	No	<ul style="list-style-type: none"> <li>-Transduction of <b>neurons and glial</b> cells.</li> <li>-wide host range.</li> <li>-large insert size up to <b>30</b> kb.</li> <li>-efficient infection.</li> </ul>	<ul style="list-style-type: none"> <li>-<b>Short-term</b> expression.</li> <li>-spreading of the infection to surrounding cell populations.</li> <li>-terminally differentiated cells.</li> <li>-immunogenic</li> </ul>



# Advantage and disadvantages of vectors $\Rightarrow$ Non viral vectors

Vector system	Advantages	Disadvantages
<b>1-Naked plasmid DNA</b>	<ul style="list-style-type: none"> <li>-simple, relatively efficient.</li> <li>-non immunogenic.</li> <li>-no mutagenesis.</li> </ul>	<ul style="list-style-type: none"> <li>-Transient gene expression.</li> <li>-DNA <b>not integrated</b> into the genome.</li> <li>- remain episomal.</li> </ul>
<b>2- Chemical vectors</b>  <i>a-Calcium phosphate</i> <i>b-Cationic liposomes (lipoplex)</i> <i>c-Polylysine-DNA complexes</i>	<ul style="list-style-type: none"> <li>- <b>Easy</b> to use.</li> <li>-Non infectious.</li> <li>-non immunogenic.</li> <li>-effective for in vivo gene transfer.</li> <li>-can carry <b>large DNA fragments</b>.</li> </ul>	<ul style="list-style-type: none"> <li>-Random integration.</li> <li>-inefficient DNA transfer.</li> <li>-Unstable.</li> <li>-<b>remain episomal</b>.</li> <li>-poor gene expression.</li> </ul>

Vector system	Advantages	Disadvantages
<b>3- Physical methods</b> <i>a- Electroporation</i> <i>b- Gene gun</i> <i>c- Microneedle injection</i>	<ul style="list-style-type: none"> <li>- <b>Easy to use.</b></li> <li>- <b>safe.</b></li> <li>- Cell receptor independent.</li> <li>- delivers genes to different tissues.</li> <li>- used in vaccine protocols.</li> <li>- increase gene expression.</li> </ul>	<ul style="list-style-type: none"> <li>- <b>Random</b> integration.</li> <li>- inefficient DNA transfer.</li> <li>- <b>No integration</b> of DNA.</li> <li>- transient gene expression.</li> <li>- Ineffective in large surface area.</li> </ul>
<b>4- Biologic non viral vectors</b> <i>(human artificial chromosomes)</i>	<ul style="list-style-type: none"> <li>- <b>Stable.</b></li> <li>- non-infectious.</li> <li>- can carry <b>large fragments of DNA.</b></li> <li>- non immunogenic.</li> <li>- no integration into the genome.</li> </ul>	<ul style="list-style-type: none"> <li>- Still in developmental stages.</li> </ul>

# Advantage and disadvantages of vectors

## ❖ *Integrating versus Non-Integrating Viruses(Viral Vectors)*

### ✓ *Integrating viruses*

- Retrovirus (e.g. murine leukemia virus)
- Adeno-associated virus (only 4kbp accommodated)
- Lentivirus

### ✓ *Non-Integrating viruses*


- Adenovirus
- Alphavirus
- Herpes Simplex Virus
- Vaccinia




# Non-viral vectors

## *Liposomes* (17)

- ✓ not limited by size or number of genes
- ✓ safe
- ✓ easy to produce
- ✓ short-term expression
- ❑ Diverse manners of 'lysing' the liposome
- ✓ Temperature sensitive
- ✓ Target sensitive
- ✓ pH sensitive
- ✓ Electric field sensitive





# *Liposomes*






# Liposomes

- Especially good for in-lung delivery (**cystic fibrosis**).<sup>(18)</sup>
- 100-1000 times more plasmid DNA needed for the same transfer efficiency as for viral vector.<sup>(18)</sup>





# *Electroporation*







# *Electroporation*

- ✓ Applying electrical pulses to cellular membranes to increase permeability.(19)
- ✓ facilitate the penetration of naked DNA molecules.(19)





# Iontophoresis

- ✓ charged molecules move according to an applied low voltage electrical current through a tissue within an electrical field.(19)
- ✓ Iontophoresis was coupled to intravitreal injection of oligonucleotides.(19)




# *Injectations of naked DNA*







# *Amino acid polymers: cationic polymers*





# *Ballistic DNA Injection (gene guns)*

- Invented for DNA transfer to plant cells
- Fully applicable to eukaryotic cells (4)



# Receptor-mediated endocytosis





Figure 21-9 Human Molecular Genetics, 3/e. (© Garland Science 2004)

Figure 21-9 Human Molecular Genetics, 3/e. (© Garland Science 2004)




# Sonoporation

- ✓ Uses ultrasonic frequencies to deliver DNA<sup>(4)</sup>
- ✓ The process disrupts the cell membrane and allows DNA to move into cells.<sup>(4)</sup>





**Sonoporation**  
ClearlyExplained.Com



# Magnetofection

- ✓ DNA is complexed to **a magnetic particles** (4)
- ✓ A magnet is placed underneath the tissue culture dish to bring DNA complexes into contact with a cell monolayer.(4)







# *Dendrimers*

- ✓ A highly branched macromolecule with a spherical shape.(17)
- ✓ The surface of the particle may be **functionalized** in many ways(17)
- ✓ In the presence of DNA or RNA charge complementarity leads to a temporary association of the nucleic acid with the cationic dendrimer
- ✓ Taken into the cell via **endocytosis**.(4)


# *Dendrimers*



# *Hybrid methods*

- ✓ Combine two or more techniques.(4)
- ✓ Virosomes are one example; they combine liposomes with an inactivated HIV or influenza virus.(4)
- ✓ More **efficient** gene transfer in respiratory epithelial cells than either viral or liposomal methods(4)


# Hybrid methods






# Oligonucleotides

- ✓ Inactivate the genes involved in the disease process.(20)
- ✓ One strategy uses **antisense** specific to the target gene to disrupt the transcription of the faulty gene.(20)




## Antisense miRNA oligonucleotide (AMO)



J Weiler et al  
Anti-miRNA oligonucleotides  
Gene Therapy (2006) 13, 496–502


# Oligonucleotides

- ✓ Another uses small molecules of RNA called **siRNA**.<sup>(4)</sup>
- ✓ To signal the cell to cleave specific unique sequences in the mRNA transcript of the faulty gene.<sup>(4)</sup>
- ✓ Disrupting **translation** of the faulty mRNA.<sup>(4)</sup>



# Gold nanomaterials

- ✓ Colloidal gold is a suspension consisting of sub-micron **gold nanoparticles** (AuNPs).(17)
- ✓ Variety of technologies including microscopy, electronics, diagnostics, and therapeutics.(17)



# *Hydrodynamic*


- ✓ A broadly used procedure for **DNA and RNA** delivery in rodents.(20)
- ✓ Serving as a **powerful tool** for gene/protein drug discovery.(4)
- ✓ Gene function **analysis, target validation, and identification** of elements in regulating gene expression.(20)
- ✓ Delivery of a variety of molecules including **circular DNA**(4)




# Hydrodynamic

- ✓ HD through mouse tail veins delivers the gene of interest most effectively to the mouse liver.(4)
- ✓ Successful HD has been achieved in the **kidneys, skeletal muscle, myocardium, hepatocellular carcinoma, and brain tumor.**(4)


## Hydrodynamic Pressure - Activated DDS





Retrieved from [www.google scholar.com](http://www.google scholar.com), 23 April 2016

## *nonviral vectors*





## References:

- 1. Culliton BJ. *Gene therapy on the move*. Nature. 1991;354:429.
- 2. <کلون سازی ژن و آنالیز DNA.pdf>.
- 3. Mohan RR, Tovey JC, Sharma A, Tandon A. *Gene therapy in the cornea: 2005–present*. Progress in retinal and eye research. 2012;31(1):43-64.
- 4. Patil P, Chaudhari P, Sahu M, Duragkar N. *Review article on gene therapy*. International Journal of Genetics. 2012;4(1):74.
- 5. Friedmann T. *A brief history of gene therapy*. Nature genetics. 1992;2(2):93-8.
- 6. Wirth T, Parker N, Ylä-Herttuala S. *History of gene therapy*. Gene. 2013;525(2):162-9.

## References:

- 7. Cotrim AP, Baum BJ. **Gene therapy: some history, applications, problems, and prospects.** Toxicologic pathology. 2008;36(1):97-103.
- 8. Hackett CS, Geurts AM, Hackett PB. Predicting preferential DNA vector insertion sites: **implications for functional genomics and gene therapy.** Genome Biol. 2007;8(Suppl 1):S12.
- 9. Emery J, Hayflick S. **The challenge of integrating genetic medicine into primary care.** Bmj. 2001;322(7293):1027-30.
- 10. Emery AE. Neuromuscular disorders: **clinical and molecular genetics:** John Wiley & Sons Incorporated; 1998.
- 11. Kantor B, Bailey RM, Wimberly K, Kalburgi SN, Gray SJ. **Methods for gene transfer to the central nervous system.** Advances in genetics. 2014;87:125.

## References:

- 12. Kassim SH, Wilson JM, Rader DJ. Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies. *Clinical lipidology*. 2010;5(6):793-809.
- 13. Williams PD, Ranjzad P, Kakar SJ, Kingston PA. Development of viral vectors for use in cardiovascular gene therapy. *Viruses*. 2010;2(2):334-71.
- 14. Wildner O, Morris J, Vahanian N, Ford H, Ramsey W, Blaese R. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. *Gene therapy*. 1999;6(1):57-62.
- 15. Flotte T. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. *Gene therapy*. 2004;11(10):805-10.
- 16. Murphy AM, Rabkin SD. Current status of gene therapy for brain tumors. *Translational Research*. 2013;161(4):339-54.



## References:

- 17. <Polymers and Nanomaterials for Gene Therapy-Woodhead Publishing (2016).pdf>.
- 18. Kane JR, Miska J, Young JS, Kanojia D, Kim JW, Lesniak MS. Sui generis: gene therapy and delivery systems for the treatment of glioblastoma. Neuro-oncology. 2015;17(suppl 2):ii24-ii36.
- 19. Trapani I, Puppo A, Auricchio A. Vector platforms for gene therapy of inherited retinopathies. Progress in retinal and eye research. 2014;43:108-28.
- 20. <Nonviral Vectors for Gene Therapy.pdf>.

*Thanks for your attention*

